 |
|
Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal Metastases
Marc C. Chamberlain, MD;
Patty Kormanik, RN, MS;
Stephen B. Howell, MD;
Sinil Kim, MD
Arch Neurol. 1995;52(9):912-917.
Abstract
Purpose
To study the results of intralumbar administration of chemotherapeutic agents for the treatment of neoplastic meningitis and to determine how these results relate to the variable and often subtherapeutic drug concentrations in the ventricular cerebrospinal fluid (CSF) compartment. Ventricular and lumbar pharmacokinetic studies were done following intralumbar administration of DTC-101, an extended-release formulation of cytarabine.
Patients and Methods
Nine patients (age range, 23 to 67 years; median age, 42 years) with leptomeningeal metastases were treated with 18 courses of intralumbar DTC-101. Eight patients who were treated with 14 courses underwent pharmacokinetic CSF sampling from the lumbar sac and lateral ventricle. Cytarabine concentrations were determined by using high-pressure liquid chromatography.
Results
Following intralumbar administration of DTC-101, therapeutic free cytarabine concentrations were achieved rapidly in both of the ventricular and lumbar CSF compartments and maintained for 2 weeks. The mean pharmacokinetic parameters of free cytarabine in the lumbar and ventricular CSF compartments were as follows: maximum concentration, 226 and 6.06 mg/L; half-life, 277 and 130 hours; and area under the concentration vs time curve, 4120 and 598 µg/h per milliliter, respectively.
Conclusions
Intralumbar administration of DTC-101 results in extended cytotoxic free cytarabine concentrations in both of the lumbar and ventricular regions of CSF and allows an every-other-week drug-dosing schedule.
Author Affiliations
From the Departments of Neurosciences (Dr Chamberlain), Nursing (Ms Kormanik), and Medicine (Drs Howell and Kim), University of California—San Diego, La Jolla. Drs Howell and Kim are shareholders of Depo Tech Corp, La Jolla.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-term Intrathecal Liposomal Ara-C Combined with Dose-dense Temozolomide
HOFFMANN et al.
Anticancer Res 2009;29:5191-5195.
ABSTRACT
| FULL TEXT
Intrathecal Therapy with Liposomal Cytarabine Plus Radiotherapy in Ph+ Acute Myeloid Leukemia Patient with Central Nervous System (CNS) Involvement.
Ardizzone et al.
ASH ANNUAL MEETING ABSTRACTS 2007;110:4364-4364.
ABSTRACT
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
Jabbour et al.
Blood 2007;109:3214-3218.
ABSTRACT
| FULL TEXT
Liposomal Cytarabine in the Central Nervous System (CNS) Prophylaxis of Elderly Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) and Undifferentiated Acute Leukemia (UAL): Preliminary Results of a Single-Center Experience.
Anaclerico et al.
ASH ANNUAL MEETING ABSTRACTS 2006;108:4663-4663.
ABSTRACT
The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe
Mazhar et al.
Blood 2006;107:3412-3414.
FULL TEXT
Phase I Trial of Intrathecal Liposomal Cytarabine in Children With Neoplastic Meningitis
Bomgaars et al.
JCO 2004;22:3916-3921.
ABSTRACT
| FULL TEXT
Intrathecal Depot Cytarabine Therapy: A Welcome Addition to a Limited Armamentarium
Bleyer
Clin. Cancer Res. 1999;5:3349-3351.
FULL TEXT
A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors
Glantz et al.
Clin. Cancer Res. 1999;5:3394-3402.
ABSTRACT
| FULL TEXT
|
